Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budenofalk 9mg OD vs 3mg TID in Active Crohn's Disease
NCT01086553Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Nov 2009
- Primary completion
- May 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide in Crohn's disease (2 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Rate of clinical remission (CDAI < 150) at 8 weeks. Started Nov 2009; status: completed.
02
Drugs
budesonide
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01086553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01086553.